# IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

> **NCT03029611** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 11 (actual)

## Conditions studied

- Stage III Fallopian Tube Cancer
- Stage III Ovarian Cancer
- Stage III Primary Peritoneal Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer

## Interventions

- **DRUG:** Carboplatin
- **PROCEDURE:** Gynecological Surgical Procedure
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine

## Key facts

- **NCT ID:** NCT03029611
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-03
- **Primary completion:** 2018-10-17
- **Final completion:** 2019-12-10
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Terminated due to lack of funding
- **Last updated:** 2022-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029611, "IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03029611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*